Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Initiator Pharma Q2 - Financed to explore vulvodynia

Initiator Pharma

Redeye provides a research update following the Q2 report recently published by Initiator Pharma. While the company is still awaiting a licensing deal for pudafensine within the ED indication, Initiator Pharma has now expanded its clinical pipeline into vulvodynia. Strengthened by the recent rights issue and the financial backing by MAC Clinical Research, the planned phase IIa trial marks a strategic move into female-focused indications with high unmet medical need and commercial potential. Following this, we make some changes to our valuation model. However, we reiterate our base case valuation of SEK15.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Initiator Pharma Q2 - Financed to explore vulvodynia

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.